uniQure to Participate in Multiple Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in October:

• 2019 Cantor Global Healthcare Conference, October 2 – 4, New York City.
  
  
  
  °  , chief executive officer at uniQure, will present a corporate update on Wednesday, October 2, at 9:30 a.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
  
   
• 2019 Cell & Gene Meeting on the Mesa, October 2 – 4, Carlsbad, California.
  
  
  
  °  , chief business officer at uniQure, will participate in a panel discussion "Cell and Gene Therapy for Neurological Product Indications" on Wednesday October 2, at 4:00 p.m. PT.
  
  °  Mr. Garen also will present a corporate update on Wednesday, October 2, at 2:45 p.m. PT.
  
   
• National Hemophilia Foundation 71^st Bleeding Disorders Conference, October 3 – 5, Anaheim, California.
  
  
  
  °  uniQure will deliver the following presentations during the conference:
  
  
  
      •  Title: No Evidence of Germline Transmission of Vector DNA Following Intravenous Administration of AAV5-hFIX to Male Mice
  
          Abstract number: CRA21
  
          Presentation date: Friday, October 4
  
          Presentation time: 5:15 – 6:15 p.m. PT
  
  
  
      •  Title: AMT-061 (AAV5-Padua hFIX variant) an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Follow-up up to 9 Months in a Phase 2b trial
  
          Abstract number: QOL29
  
          Presentation date: Friday, October 4
  
          Presentation time: 5:15 – 6:15 p.m. PT
  
  
  
      •  Title: An Evaluation of Health Utility and Quality-of-Life in Hemophilia: A Systematic Literature Review
  
          Presentation date: Friday, October 4
  
          Presentation time: 5:15 – 6:15 p.m. PT

• European Huntington Association 2019 Conference, October 4 – 6, Bucharest, Romania.
  
  
  
  °  Melvin Evers, Ph.D., associate director research at uniQure, will be presenting on the Company’s gene therapy candidate AMT-130 for Huntington’s disease on Sunday October 6, at 10:30 a.m. CET.
  
  °  Dr. Evers will also participate in a panel discussion at the conclusion of the presentation session "Drug Trials in Huntington’s Disease: What is Happening Right Now?" at 11:20 a.m. CET.
  
   
• Chardan 3rd Annual Genetic Medicines Conference, October 7 – 8, New York City
  
  
  
  °  Matt Kapusta will participate in a fireside chat with research analyst Gbola Amusa on Tuesday, October 8, at 11:00 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
  
   
• European Society for Gene and Cell Therapy 2019 Collaborative Congress, October 22 – 25, Barcelona, Spain.
  
  
  
  °  uniQure will deliver the following presentations during the conference:
  
  
  
      •  Title: A Novel AAV-Based miQURE Gene Therapy for Spinocerebellar Ataxia Type 3
  
          Abstract number: P247
  
          Presentation date: Wednesday, October 23
  
          Presentation time: 1:00 – 2:30 p.m. CET
  
  
  
      •  Title: Stem Cell Derived Brain Organoids, a Promising Model to Study Adeno Associated Viruses for CNS Gene Therapy
  
          Abstract number: P381
  
          Presentation date: Wednesday, October 23
  
          Presentation time: 1:00 – 2:30 p.m. CET
  
          
  
      •  Title: Prevalence and Affinity/Avidity Assessment of Pre-Existing NABs Against AAV2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors
  
          Abstract number: P336
  
          Presentation date: Thursday, October 24
  
          Presentation time: 1:00 – 2:30 p.m. CET

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts: